GILEAD SCIENCES INC Insider Trading for March 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GILEAD SCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in GILEAD SCIENCES INC for March 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | M | 16.40 | 90,000 | 1,475,550 | 430,000 | |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 76.83 | 2,700 | 207,454 | 119,302 | 122 K to 119.3 K (-2.21 %) |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 76.25 | 48,488 | 3,697,433 | 122,002 | 170.5 K to 122 K (-28.44 %) |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 75.36 | 38,812 | 2,924,818 | 170,490 | 209.3 K to 170.5 K (-18.54 %) |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Buy | M | 16.40 | 90,000 | 1,475,550 | 209,302 | 119.3 K to 209.3 K (+75.44 %) |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 14.34 | 14,000 | 200,725 | 91,000 | |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 77.07 | 200 | 15,414 | 39,542 | 39.7 K to 39.5 K (-0.50 %) |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 76.43 | 13,800 | 1,054,687 | 39,742 | 53.5 K to 39.7 K (-25.77 %) |
| Mar 18 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 14.34 | 14,000 | 200,725 | 53,542 | 39.5 K to 53.5 K (+35.41 %) |
| Mar 12 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 21.58 | 16,728 | 360,907 | 7,904 | |
| Mar 12 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 79.32 | 16,728 | 1,326,833 | 28,562 | 45.3 K to 28.6 K (-36.94 %) |
| Mar 12 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 21.58 | 16,728 | 360,907 | 45,290 | 28.6 K to 45.3 K (+58.57 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Payment of Exercise | F | 79.92 | 40,180 | 3,211,186 | 86,652 | 126.8 K to 86.7 K (-31.68 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 77,000 | 0 | 126,832 | 49.8 K to 126.8 K (+154.52 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Payment of Exercise | F | 79.92 | 54,790 | 4,378,817 | 119,302 | 174.1 K to 119.3 K (-31.47 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 105,000 | 0 | 174,092 | 69.1 K to 174.1 K (+151.97 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 21.94 | 968 | 21,243 | 69,092 | 68.1 K to 69.1 K (+1.42 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Payment of Exercise | F | 79.92 | 187,848 | 15,012,812 | 4,429,387 | 4.6 M to 4.4 M (-4.07 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 0.00 | 360,000 | 0 | 4,617,235 | 4.3 M to 4.6 M (+8.46 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Payment of Exercise | F | 79.92 | 11,280 | 901,498 | 28,562 | 39.8 K to 28.6 K (-28.31 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 0.00 | 24,000 | 0 | 39,842 | 15.8 K to 39.8 K (+151.50 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Payment of Exercise | F | 79.92 | 82,968 | 6,630,803 | 938,048 | 1 M to 938 K (-8.13 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Grant | A | 0.00 | 159,000 | 0 | 1,021,016 | 862 K to 1 M (+18.45 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Grant | A | 21.94 | 968 | 21,243 | 862,016 | 861 K to 862 K (+0.11 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Payment of Exercise | F | 79.92 | 54,790 | 4,378,817 | 134,694 | 189.5 K to 134.7 K (-28.92 %) |
| Mar 10 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 0.00 | 105,000 | 0 | 189,484 | 84.5 K to 189.5 K (+124.28 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 8.01 | 140,625 | 1,125,703 | 1,265,633 | |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 82.36 | 40,958 | 3,373,452 | 4,257,235 | 4.3 M to 4.3 M (-0.95 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 81.49 | 99,667 | 8,121,874 | 4,298,193 | 4.4 M to 4.3 M (-2.27 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 8.01 | 140,625 | 1,125,703 | 4,397,860 | 4.3 M to 4.4 M (+3.30 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 21.94 | 968 | 21,243 | 4,257,235 | 4.3 M to 4.3 M (+0.02 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 21.58 | 31,000 | 668,825 | 27,367 | |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 82.53 | 500 | 41,265 | 84,484 | 85 K to 84.5 K (-0.59 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 81.66 | 1,500 | 122,495 | 84,984 | 86.5 K to 85 K (-1.73 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 82.36 | 3,931 | 323,753 | 86,484 | 90.4 K to 86.5 K (-4.35 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 81.76 | 27,069 | 2,213,175 | 90,415 | 117.5 K to 90.4 K (-23.04 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 21.58 | 31,000 | 668,825 | 117,484 | 86.5 K to 117.5 K (+35.84 %) |
| Mar 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 21.94 | 968 | 21,243 | 86,484 | 85.5 K to 86.5 K (+1.13 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 24.91 | 3,000 | 74,715 | 6,000 | |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 24.30 | 11,250 | 273,319 | 90,000 | |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 23.76 | 4,800 | 114,024 | 19,200 | |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 19.09 | 11,550 | 220,432 | 46,200 | |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Gift | G | 0.00 | 350 | 0 | 26,780 | 27.1 K to 26.8 K (-1.29 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 84.05 | 8,846 | 743,497 | 49,832 | 58.7 K to 49.8 K (-15.08 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 83.63 | 19,276 | 1,612,009 | 58,678 | 78 K to 58.7 K (-24.73 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 82.38 | 2,478 | 204,129 | 77,954 | 80.4 K to 78 K (-3.08 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 24.30 | 11,250 | 273,319 | 80,432 | 69.2 K to 80.4 K (+16.26 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 19.09 | 11,550 | 220,432 | 69,182 | 57.6 K to 69.2 K (+20.04 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 23.76 | 4,800 | 114,024 | 57,632 | 52.8 K to 57.6 K (+9.09 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 24.91 | 3,000 | 74,715 | 52,832 | 49.8 K to 52.8 K (+6.02 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Option Exercise | M | 0.00 | 167 | 0 | 23,104 | |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Buy | M | 0.00 | 167 | 0 | 14,952 | 14.8 K to 15 K (+1.13 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 24.91 | 30,000 | 747,150 | 40,000 | |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 23.60 | 69,000 | 1,628,400 | 0 | |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 83.55 | 99,000 | 8,271,935 | 15,842 | 114.8 K to 15.8 K (-86.21 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 24.91 | 30,000 | 747,150 | 114,842 | 84.8 K to 114.8 K (+35.36 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 23.60 | 69,000 | 1,628,400 | 84,842 | 15.8 K to 84.8 K (+435.55 %) |
| Mar 04 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 21.94 | 709 | 15,559 | 15,842 | 15.1 K to 15.8 K (+4.69 %) |